Key Laboratory of Medical Molecular Virology, Institutes of Biomedical Sciences and Institute of Medical Microbiology, Fudan University, Shanghai 200032, China.
Antimicrob Agents Chemother. 2010 Mar;54(3):1075-81. doi: 10.1128/AAC.00964-09. Epub 2009 Dec 14.
Novel tools are urgently needed for the rapid, reliable detection of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis. To develop such tools, we need information about the frequency and distribution of the mycobacterial mutations and genotypes that are associated with phenotypic drug resistance. In a population-based study, we sequenced specific genes of M. tuberculosis that were associated with resistance to rifampin and isoniazid in 242 phenotypically MDR isolates and 50 phenotypically pan-susceptible isolates from tuberculosis (TB) cases in Shanghai, China. We estimated the sensitivity and specificity of the mutations, using the results of conventional, culture-based phenotypic drug susceptibility testing as the standard. We detected mutations within the 81-bp core region of rpoB in 96.3% of phenotypically MDR isolates. Mutations in two structural genes (katG and inhA) and two regulatory regions (the promoter of mabA-inhA and the intergenic region of oxyR-ahpC) were found in 89.3% of the MDR isolates. In total, 88.0% (213/242 strains) of the phenotypic MDR strains were confirmed by mutations in the sequenced regions. Mutations in embB306 were also considered a marker for MDR and significantly increased the sensitivity of the approach. Based on our findings, an approach that prospectively screens for mutations in 11 sites of the M. tuberculosis genome (rpoB531, rpoB526, rpoB516, rpoB533, and rpoB513, katG315, inhA-15, ahpC-10, ahpC-6, and ahpC-12, and embB306) could detect 86.8% of MDR strains in Shanghai. This study lays the foundation for the development of a rapid, reliable molecular genetic test to detect MDR strains of M. tuberculosis in China.
目前迫切需要开发新型工具,以快速、可靠地检测耐多药(MDR)和广泛耐药(XDR)结核分枝杆菌。为了开发这些工具,我们需要了解与表型药物耐药性相关的分枝杆菌突变和基因型的频率和分布。在一项基于人群的研究中,我们对来自中国上海结核病(TB)病例的 242 株表型 MDR 分离株和 50 株表型全敏感分离株中与利福平及异烟肼耐药相关的结核分枝杆菌特定基因进行了测序。我们使用传统的、基于培养的表型药敏试验结果作为标准,评估了突变的敏感性和特异性。我们在 96.3%的表型 MDR 分离株中检测到 rpoB 81bp 核心区域内的突变。在 89.3%的 MDR 分离株中发现了两个结构基因(katG 和 inhA)和两个调节区(mabA-inhA 启动子和 oxyR-ahpC 基因间区)的突变。总共,242 株表型 MDR 分离株中有 88.0%(213 株)通过测序区域的突变得到了确认。embB306 突变也被认为是 MDR 的标志物,并显著提高了该方法的敏感性。基于我们的研究结果,一种前瞻性筛查结核分枝杆菌基因组 11 个位点突变(rpoB531、rpoB526、rpoB516、rpoB533 和 rpoB513、katG315、inhA-15、ahpC-10、ahpC-6 和 ahpC-12、embB306)的方法可检测到上海 86.8%的 MDR 菌株。本研究为开发快速、可靠的分子遗传学检测方法以检测中国的 MDR 结核分枝杆菌菌株奠定了基础。